Clinical Trial

Laparoscopic Pancreaticoduodenectomy

Study acronym: LPD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Laparoscopic pancreaticoduodenectomy was first performed by Garner and Pomp in 1994. This is a technically difficult, time consuming and high rate of complication procedure. The reason is that duodenum and head of pancreas locate deeply in retroperitoneum and are surrounded by important structures such as inferior vena cava, abdominal aorta, superior mesenteric artery, superior mesenteric vein (SMV), portal vein (PV) and hepatic arteries. Injuring these structures during the surgery can lead to life-threatening complications. Moreover, doing anastomoses through laparoscopy, especially pancreatic anastomosis, is more difficult and takes more time than through open approach. The outcome of PD has improved over the last two decades due to advances in surgical techniques, anesthesia and perioperative care. Although studies from high volume centers demonstrate reduce in the operative mortality to less than 3%, the postoperative morbidity rate is still ranging from 30% to 60%. Laparoscopic surgery is being used increasingly as a less invasive alternative to traditional interventions for pancreatic resection. Laparoscopic pancreaticoduodenectomy (LPD) is a difficult procedure that has become increasingly popular. Nevertheless, comparative data on outcomes remain limited. In this prospective study, investigators evaluate the safety and feasibility of surgical and oncological outcomes of minimally invasive PD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-05; most recent amendment 2025-08-22.
Status change: Not Yet Recruiting → Recruiting 2025-06-06
Trial Details
NCT Number NCT07009119
Lead Sponsor Minia University
Conditions Pancreatic Cancer, Pancreatic Fistula, Periampullary Cancer
Enrollment 30 participants
Start Date 2025-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-29